These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 383581)

  • 61. Role of suppressor T cells in lymphopoietic disorders.
    Steinberg AD; Klassen LW
    Clin Haematol; 1977 Jun; 6(2):439-78. PubMed ID: 71963
    [No Abstract]   [Full Text] [Related]  

  • 62. [Tumors as allotransplants: neoplastic immunodepression and prospects of immunotherapy].
    Clerici E
    Ann Laringol Otol Rinol Faringol; 1975; 74(1):45-65. PubMed ID: 801853
    [No Abstract]   [Full Text] [Related]  

  • 63. [Disorders in the resistance to infections].
    Schumacher K
    Verh Dtsch Ges Inn Med; 1978; (84):472-81. PubMed ID: 311121
    [No Abstract]   [Full Text] [Related]  

  • 64. [Principles of immune defects].
    Mäkelä O; Tiilikainen A
    Duodecim; 1985; 101(3):341-7. PubMed ID: 3872208
    [No Abstract]   [Full Text] [Related]  

  • 65. [Use of monoclonal antibodies in the study of the lymphoid system. II. Classification and treatment of the leukemias].
    Blanco Quirós A; Alvarez Guisasola J
    An Esp Pediatr; 1982 Jul; 17(1):48-59. PubMed ID: 6982643
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
    Seremet T; Brasseur F; Coulie PG
    Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Analysis of T-lymphocytes and B-lymphocytes].
    Nakagawa T; Yata J
    Nihon Rinsho; 1976; 34 suppl():2653-71. PubMed ID: 792528
    [No Abstract]   [Full Text] [Related]  

  • 68. [Correlations of B- and T-cell immune systems].
    Mosonyi L
    Dtsch Med Wochenschr; 1986 Aug; 111(34):1303. PubMed ID: 3488896
    [No Abstract]   [Full Text] [Related]  

  • 69. Mechanisms of tumor-induced immunological deficiencies and their possible significance in relation to the use of immunopotentiators in tumor-bearing hosts.
    Kerbel RS
    Biomedicine; 1974 Jul; 21(7):253-61. PubMed ID: 4547979
    [No Abstract]   [Full Text] [Related]  

  • 70. [Participation of lymphoid organ T- and B-lymphocytes in transplantation immunity in immune deficiency modeled with anti-thymus serum and cyclophosphamide].
    Antonenko VT; Chornen'ka VD
    Fiziol Zh; 1977; 23(6):733-40. PubMed ID: 338369
    [No Abstract]   [Full Text] [Related]  

  • 71. Basic principles of the immune response and the immunologic inhibition of tumors.
    Vorlaender KO
    Allergol Immunopathol (Madr); 1973 Jul; 1(4):235-46. PubMed ID: 4794103
    [No Abstract]   [Full Text] [Related]  

  • 72. Immune deficiency disorders.
    Berman BA; Ross RN
    Cutis; 1982 Apr; 29(4):313-4, 316, 319-20. PubMed ID: 6979465
    [No Abstract]   [Full Text] [Related]  

  • 73. Mechanisms of immunity in cancer.
    Baldwin RW
    Pathobiol Annu; 1981; 11():155-75. PubMed ID: 6460216
    [No Abstract]   [Full Text] [Related]  

  • 74. Nursing measures for the prevention of infection in the compromised host.
    Gurevich I; Tafuro P
    Nurs Clin North Am; 1985 Mar; 20(1):257-60. PubMed ID: 3919368
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cell biology: The ins and outs of exosomes.
    Couzin J
    Science; 2005 Jun; 308(5730):1862-3. PubMed ID: 15976285
    [No Abstract]   [Full Text] [Related]  

  • 76. Immune recognition of self in immunity against cancer.
    Houghton AN; Guevara-Patiño JA
    J Clin Invest; 2004 Aug; 114(4):468-71. PubMed ID: 15314682
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cell marker studies of human tumorigenesis.
    Friedman JM; Fialkow PJ
    Transplant Rev; 1976; 28():17-33. PubMed ID: 766326
    [No Abstract]   [Full Text] [Related]  

  • 78. Principles of immunological tolerance and immunocyte receptor blockade.
    Nossal GJ
    Adv Cancer Res; 1974; 20():93-130. PubMed ID: 4142364
    [No Abstract]   [Full Text] [Related]  

  • 79. How efficient is immunological surveillance against cancer and why does it fail?
    Laroye GJ
    Lancet; 1974 Jun; 1(7866):1097-1100. PubMed ID: 4135256
    [No Abstract]   [Full Text] [Related]  

  • 80. Editorial: Cancer immunotherapy.
    Hussey HH
    JAMA; 1974 Jan; 227(4):435. PubMed ID: 4543616
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.